Eli Lilly's oral GLP-1 diabetes pill orforglipron demonstrated superiority over Novo Nordisk’s Rybelsus in a phase 3 trial, edging blood sugar and weight loss. However, Novo Nordisk announced layoffs in New Jersey totaling 263 staff amidst restructuring efforts, while Bristol Myers Squibb cut 282 positions. Concurrently, the FDA issued warning letters targeting telehealth companies for misleading GLP-1 medication advertising, highlighting regulatory scrutiny in this lucrative obesity drug market. The evolving landscape signals competitive and operational pressures despite clinical advances.